MICHAEL JAMES OVERMAN to Programmed Cell Death 1 Receptor
This is a "connection" page, showing publications MICHAEL JAMES OVERMAN has written about Programmed Cell Death 1 Receptor.
Connection Strength
1.329
-
Endoscopic and imaging outcomes of PD-1 therapy in localised dMMR colorectal cancer. Eur J Cancer. 2023 11; 194:113356.
Score: 0.557
-
Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC). J Immunother Cancer. 2022 08; 10(8).
Score: 0.129
-
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer. Clin Cancer Res. 2021 03 15; 27(6):1663-1670.
Score: 0.115
-
Clinical Development of Immunotherapy for Deficient Mismatch Repair Colorectal Cancer. Clin Colorectal Cancer. 2020 06; 19(2):73-81.
Score: 0.108
-
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer. J Immunother Cancer. 2020 02; 8(1).
Score: 0.108
-
KRAS-IRF2 Axis Drives Immune Suppression and Immune Therapy Resistance in Colorectal Cancer. Cancer Cell. 2019 04 15; 35(4):559-572.e7.
Score: 0.102
-
Nivolumab in the treatment of microsatellite instability high metastatic colorectal cancer. Future Oncol. 2018 08; 14(18):1869-1874.
Score: 0.095
-
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 09; 18(9):1182-1191.
Score: 0.091
-
Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
Score: 0.024